



# Bal Pharma Limited

To,

The Manager-Listing  
National Stock Exchange of India Ltd  
Mumbai.

28.06.2024

BSE Limited  
Mumbai.

Dear Sir,

**Sub : Completion of tenure of Independent Director.**  
**Ref : Regulation 30 of SEBI(LODR) Regulations,2015.**

With reference to the above cited subject and reference, we would like to bring to the notice of the exchanges that Dr.C.V.Srinivas ( DIN # 08495304) independent Director of the Company has completed his tenure of five years as independent Director and he ceases to be on the Board of the Company w.e.f 28.06.2024.

Consequently, Dr.C.V Srinivas shall also cease to be the Chairman/Member of the Audit Committee, Nomination and Remuneration Committee, Stake Holders Relationship Committee & Corporate Social Responsibility Committees of the Company.

The information with regard to the above mentioned change in the composition of the Board in terms of Regulation 30 read with Schedule III - Para A(7B) of Part A of the Listing Regulations (as applicable) and SEBI Circular bearing Ref. No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is enclosed herewith.

We request you to please take this intimation on record.

**For Bal Pharma Limited**

## Authorized Signatory.

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. :080-41570811 / 13 / 19 Fax : 41570820

**Information as required under Regulation 30 - Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.**

<b>SI No</b>	<b>Particulars</b>	<b>Description</b>
01.	Reasons for Change	Completion of tenure of Dr. C.V Srinivas as Independent Director of the Company.
02.	Date of Cessation	28.06.2024
03.	Brief Profile	Not Applicable
04.	Disclosure of Relationship between Directors of the Board	Not Applicable
05.	Information as required under BSE & NSE circular # LIST/COM/14/2018-19 and NSE/CML/2018/24 respectively.	Not applicable